Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bounced off 52 week low. Looking for a reversal here
Thank you for your thoughts.
Just doing some DD currently.
support at 2.18 - if it goes lower we may see $1.25 to $1.50 area
the charts are bearish, the just approved drug won't go on sale until April to June 2019.
Each one year prescription of the drug will cost to patient $300,000 per year -- what insurance company or individual can afford that?
Agree with xlofer, CPRX $66 million cash, no debt & on last CC clearly stated they're good thur 2019. The FUD from short sellers is criminal behavior.
Stop writing bull crap about dilution there is No dilution why Not being a Man say it loud that you R shorting the stock, read the last CC, CEO was very clear No Need for offering enough cash to launch. Clay and the gang misleading people.
* * $CPRX Video Chart 11-30-18 * *
Link to Video - click here to watch the technical chart video
Diluting into the FDA approval news. Watch for bottom and end of dilution
Diluting into the FDA approval news. Watch for bottom and end of dilution
* * $CPRX Video Chart 11-29-18 * *
Link to Video - click here to watch the technical chart video
is it true that this is so rare it only affects in in a million....
Halt in trading for news is ongoing--3:16 and pending. At 4:12 this PR:
Catalyst Pharmaceuticals Inc. (Nasdaq:CPRX) today reports that no decision has yet been received from the Food and Drug Administration with respect to the company’s new drug application for Firdapse. The company reported that a contractor working on a web page unintentionally allowed a live screen to be seen that reflected that the possible approval of the company’s NDA had already been received.
The company is issuing this release in order to clarify to the marketplace the status of its NDA.
$4 plus today would be good. $4.50 plus by end of week.
Day of reckoning...wait for it....
Wait for it....Wait for it.....Wait for it.....
Earnings release and corporate update after hours...conference call at 8:30 am on 11/08/2018.
https://ih.advfn.com/p.php?pid=nmona&article=78638187
https://pressoracle.com/2018/10/28/catalyst-pharmaceuticals-inc-cprx-shares-bought-by-blackrock-inc.html
BlackRock Inc. grew its position in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) by 29.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,059,627 shares of the biopharmaceutical company’s stock after acquiring an additional 1,361,096 shares during the quarter. BlackRock Inc. owned about 5.91% of Catalyst Pharmaceuticals worth $18,905,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. GSA Capital Partners LLP raised its stake in shares of Catalyst Pharmaceuticals by 295.7% during the second quarter. GSA Capital Partners LLP now owns 380,605 shares of the biopharmaceutical company’s stock worth $1,187,000 after purchasing an additional 284,409 shares during the last quarter. Northern Trust Corp raised its stake in shares of Catalyst Pharmaceuticals by 22.5% during the first quarter. Northern Trust Corp now owns 1,009,947 shares of the biopharmaceutical company’s stock worth $2,414,000 after purchasing an additional 185,639 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the second quarter worth approximately $476,000. Bank of New York Mellon Corp raised its stake in shares of Catalyst Pharmaceuticals by 15.7% during the second quarter. Bank of New York Mellon Corp now owns 274,813 shares of the biopharmaceutical company’s stock worth $858,000 after purchasing an additional 37,388 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of Catalyst Pharmaceuticals by 24.3% during the first quarter. Schwab Charles Investment Management Inc. now owns 184,904 shares of the biopharmaceutical company’s stock worth $442,000 after purchasing an additional 36,200 shares during the last quarter. 51.49% of the stock is owned by institutional investors and hedge funds.
Sold CPRX. Bought OVID. CP115 pipeline growth was extremely disappointing last couple of years. Going nowhere fast!
Earnings Conference call / Decrease in share price = embarrassing situation for stakeholders.
Short time-frame for whatever satisfies FDA will do.
I know. What can I say? It will happen when "show me the money" becomes evident. LOL.
That announcement did nothing for share price today; we wait for tomorrow like many others.
Roth Capital raised its price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) to $6.00 (from $4.75) while maintaining a Buy rating following 4Q release. CPRX reported a 4Q EPS loss of $0.06, versus a targeted loss of $0.07. The company reached agreement with the FDA under a Special ...https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Catalyst+Pharmaceutical+Partners+%28CPRX%29+PT+Raised+to+%246+at+Roth+Capital+Following+4Q/13962031.html
Sure. I didn't think of copying and pasting the content. Will do next time.
Thanks, hump4, for the link[more to chat about at lunch ~2 weeks]:
"Teachers Advisors LLC bought a new stake in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 126,696 shares of the biopharmaceutical company’s stock, valued at approximately $350,000. Teachers Advisors LLC owned approximately 0.15% of Catalyst Pharmaceuticals as of its most recent filing with the SEC.
Several other large investors have also made changes to their positions in CPRX. Bank of New York Mellon Corp lifted its stake in Catalyst Pharmaceuticals by 3.6% during the first quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock valued at $135,000 after purchasing an additional 2,404 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Catalyst Pharmaceuticals during the first quarter valued at approximately $155,000. Vanguard Group Inc. lifted its stake in Catalyst Pharmaceuticals by 0.5% during the first quarter. Vanguard Group Inc. now owns 3,007,935 shares of the biopharmaceutical company’s stock valued at $5,865,000 after purchasing an additional 15,600 shares during the last quarter. Geode Capital Management LLC lifted its stake in Catalyst Pharmaceuticals by 0.3% during the first quarter. Geode Capital Management LLC now owns 462,677 shares of the biopharmaceutical company’s stock valued at $902,000 after purchasing an additional 1,446 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 1st quarter valued at approximately $746,000. 41.31% of the stock is owned by institutional investors and hedge funds."
52 week highs! growing momo!
Awesome a secondary offering announced!!!!!
Positive phase 3 trial. 3.80 tough resistance. Breaking 3.80 could run us a bit
I think this one is going to see a bigger break out soon enough. Will it happen in a week or two months I do not know but I think it does happen.
That is a good thing and another good thing. Joined the Russell 3000. Actually quite happy it is not a cult stock and people only post new and pertinent information not regurgitating the same old news and data.
I think many of us are just being patient and letting the stock to do its thing. I get being optimistic about your stock but all the chatter about being bought out and its going to see $80 in a week is for the new traders. The people that have been around awhile in the market try to be a little more down the earth and just trust we are in a solid stock. I really feel right now someone thinks Firdapse gets the thumbs up from the FDA soon. Will be big for this little company. Has a very small market cap for a drug with such a big money maker. Looks to me like as we get closer to hearing from the FDA that this one stays hot.
Hard to believe no one here and this stock has been on fire. Meanwhile over at another bio I am invested in the CEO so much as coughs and their is all this wild and rampant speculation about they becoming a BP overnight with all these unrealistic scenarios or the pps is going to skyrocket to triple digits in a short time frame, posts of misinterpreted T/A and out of touch pumps on how that single drug is going to solve all of man kinds CNS issues over night. On second thought am glad this does not have a cult following here!!!
I think so after the shock of yesterday but wow what a day today, new 52 week high and big blocks getting gobbled up.
Delayed reaction to this news today?:
CPRX News: Catalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Trials XIV Symposium
http://ih.advfn.com/p.php?pid=nmona&article=74627412
Replay of CC is here https://www.investornetwork.com/company/23809
Earnings and CC today and no interest here. I guess it is not a volatile and speculative enough stock to garner the attention of traders who make up the majority of people on here and very few actual investors.
Still little to no activity here. I guess their is not a fanatical cult following here with a company that has potential like on some other boards.
looks like new Shorts came in from $ 2.04 area
might need to cool off a little
GLTA
my European , ipci friend ,
that remoxy thing at ptie IS very interesting .......... THANKS
will keep an eye on it ( ptie , that is )
be well
thanks !
This thing looks like it could ( and will ) keep moving higher ,
even though all T/A indicators are ( have been ) in overheated = over bought territory !
Today's action indicated a SOLID buying ( or Short Covering )
either way , a STRONG base is being set up in the low 1.90's
IMHO , this thing will be climbing up AGAIN .............
go CPRX
Followers
|
183
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
4126
|
Created
|
04/23/07
|
Type
|
Free
|
Moderators |
Q2-19 Financial Results
Recent Developments and Highlights
Upcoming Milestones
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |